Untangling the web of price reductions:

a pricing guide for the purchase of ARVs for developing countries

8th Edition

June 2005
# Table of contents

3 Table of contents
4 General background and objectives
5 Methodology
6 Analysis of current offers limitations: are products getting to patients in need?
8 Graph 1: Comparison between prices published in this report and prices reported by Global Fund
9 Graph 2: Prices of medicines recommended as 1st and 2nd line by WHO, January 2005
10 Graph 3: The Effects of Generic Competition
12 Table 1: 1st and 2nd category of prices offered by manufacturers for the different countries (yearly and unit price)
15 Table 2: Summary table for conditions
17 Annexes
  17 Annex 1: Least Developed Countries (LDCs)
  17 Annex 2: Human Development Index (HDI)
  17 Annex 3: Sub-Saharan countries
18 Annex 4: World Bank low-income and low-middle-income countries
18 Annex 5: Company contacts
20 Glossary
1. General background and objectives
This is the eighth edition of *Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries*. The report was first published by Médecins Sans Frontières (MSF) in October 2001 \(^1\) in response to the lack of transparent and reliable information about prices of pharmaceutical products on the international market – a factor which significantly hampers access to essential medicines in developing countries. The situation is particularly complex in the case of antiretrovirals (ARVs). The purpose of this document is to provide information on prices and suppliers that will help purchasers make informed decisions when buying ARVs.

Since the first edition of “Untangling”, prices of some first-line ARVs have fallen significantly due to competition between multiple producers. However, not all countries are able to benefit from these lower prices because of patent barriers to accessing generic versions. Price and availability of newer ARVs are still significant obstacles to access to treatment. This report shows that the prices of second-line drugs are six to twelve times \(^1\) higher than those of older first-line treatments, in Least Developed Countries (LDCs) and sub-Saharan Africa. In the case of some of the second-line ARVs, it is lack of competition that has led to high prices (see graph 2). In some developing countries outside sub-Saharan Africa, the prices of both first- and second-line drugs mirror those charged in wealthy countries.

MSF has found that problems fall into three categories: 1) some single-source drugs are very expensive, 2) differential prices are not really available as advertised in developing countries because some companies do not register their products in poor countries, and 3) some companies do not offer discounted prices in middle-income countries.

Brazil is a good illustration of problems encountered in middle-income countries. Brazil currently spends 63% percent of its total ARV drug budget on three products (Abbott’s lopinavir/ritonavir, Gilead’s tenofovir and Merck’s efavirenz). In theory, a government such as Brazil’s can overcome this problem by using compulsory licensing to override patents or intellectual property barriers. These mechanisms are in-built flexibilities of the World Trade Organization’s TRIPS Agreement and have been affirmed in the Doha Declaration on TRIPS and Public Health in 2001 \(^2\).

Following the adoption of the Doha Declaration, Least Developed Countries (LDCs) are no longer obliged under the WTO rules to grant or enforce pharmaceutical product patents until at least 2016.

The use of these flexibilities and safeguards is particularly important since India, the biggest producer of generic drugs, is now obligated to grant patents on new pharmaceutical products. The new Indian Patents Act will not affect medicines that were invented before 1995. However, patent applications filed between 1995 and 2005 will be reviewed by Indian patent authorities and patents may subsequently be granted.

If a patent is granted, it will not stop a generic manufacturer from continuing to produce and market the drug in India if they have made a “significant investment”, as the new Indian law stipulates an automatic licensing system which will allow for the continued production of the generic version if a “reasonable royalty” is paid. But when patents are granted for applications submitted after January 2005, only patent holders will have the right to produce these drugs unless India and other countries issue compulsory licenses to give others the right to produce, market and export the product \(^3,4\).

Treatment of HIV/AIDS in children deserves special attention: most companies produce syrups and oral solutions, which are ill-adapted for use in developing countries because caregivers have problems reconstituting syrups, as well as measuring and preserving them. Pharmaceutical companies are not investing enough resources in the development of paediatric formulations, since it is a small and risky market that is also of diminishing importance in Western countries \(^5\). In addition to this, the price of liquid and solid drugs in paediatric formulations is higher than that of their adult equivalents. For instance, treating a child weighing 10

---

\(^1\) Comparison between the triple fixed-dose combination (3TC/d4T/NVP) and best available prices for WHO recommended 2nd line regimens. Only WHO prequalified products or products registered in highly regulated countries were compared.
kg for one year with stavudine, nevirapine and lamivudine can cost up to US$816, while treating an adult with the same drugs costs US$182.

This document complements the information in the pricing guide Sources and Prices of selected medicines and diagnostics for People living with HIV/AIDS published by UNICEF/UNAIDS/WHO/MSF.


2. Methodology
To obtain accurate information, MSF has contacted both originator and generic companies and asked them to provide the following information about the ARVs offered to developing countries: dosage and pharmaceutical form, price per unit (or daily dose), restrictions that apply to the offers (eligibility), and any additional specificity of the offers.

Products listed here have been approved for marketing at least in their countries of origin. The list of generic producers included in this report is by no means exhaustive. These companies were mostly chosen because they have publicly announced price offers to developing countries.

All prices are quoted in US dollars and conversions have been made on the day the price information was received using the currency converter site: www.oanda.com.

We acknowledge the difficulties and inaccuracies when establishing price comparisons across different countries and purchasers, and therefore recommend that these prices be considered in relative and not absolute terms.

Table 1: First and Second Category of Prices offered by manufacturers for the different countries (yearly and unit prices)

Generic companies do not apply any geographical restriction.

Most originator companies offer their discounted prices only to a certain group of countries, normally only to LDCs and sub-Saharan African countries. These prices are referred to as FIRST CATEGORY PRICES. See table 2 for details.

There are exceptions such as Gilead and Bristol-Myers Squibb that have recently, for example, extended their first category of price to some middle-income countries, or Merck, which applies first category prices also to medium human development index countries when the country's HIV prevalence is greater than 1%, or GlaxoSmithKline, which has offered their products for all Global Fund recipient countries.

Finally, companies like Merck and Roche offer a SECOND CATEGORY OF PRICES for middle-income countries (almost twice as much as the first category price). When these second...
category prices exist, they have been included in the table.

Prices are rounded up to the third decimal for unit price and to the nearest whole number for yearly price per patient.

Prices quoted by the different companies are not always directly comparable since companies use different trade terms (incoterm[s]). Prices quoted by Roche, all generic companies, Abbott and Gilead are so-called “FCA” or “FOB” prices which means that transport, international freight and insurance costs are not included; the other companies mentioned in this report do include freight and insurance in their prices. Despite this fact, in this edition the prices have not been adjusted, following the methodology used in the US General Accountability Office (GAO) report[9].

For all paediatric treatments, prices are calculated for a 10 kg child using WHO treatment guidelines. This is an estimate since the weight of a child increases during any given year. The annual cost of treatment has been calculated according to WHO dosing schedules[11] multiplying the unit price (price of e.g. one tablet or capsule) by the number of units required for the daily dose and by 365 days in a year. Price is then presented in USD/year, and in brackets, the price per smallest unit is quoted.

The price of products prequalified by WHO are based on the 23rd edition of the WHO prequalification list (April 4th 2005) and appear in bold. Please consult the latest WHO prequalification list for more details regarding manufacturing sites.

Table 2: Conditions of offer by company

Conditions applying to each company’s offer were quoted directly by companies.

There is no uniformity concerning geographical restrictions to the offers but rather each originator company establishes different limits to their offer for different categories of countries (annex 1-4). Some companies use UNCTAD (Least Developed Countries) criteria, others the UNDP Human Development index, and yet others the World Bank classification.

There are significant differences between categories used by companies. For instance, 15 countries are considered Least Developed Countries (LDCs) by UNCTAD, but are placed in the medium level by UNDP. These include Bangladesh, Cambodia, Laos and Sudan. Six other LDCs do not appear in the UNDP classification at all, including Democratic Republic of Congo, Liberia and Somalia.

Furthermore, many developing countries are left out of the differential pricing scheme altogether. These include Bolivia, Nicaragua, Thailand, Ukraine and Vietnam for the UNDP classification, China, Honduras and Sri Lanka for the World Bank classification, and all Latin American countries except Haiti for the UNCTAD classification.

3. Analysing the limitations of current offers: are products getting to patients in need?

3.1. Availability in countries?

The products listed in this report are not always available in every country. There are several reasons for this:

Even when price reductions have been announced, the products are not necessarily marketed in all the eligible countries

- MSF projects have experienced this situation in many cases, even in the poorest nations such as Mozambique or Cambodia, where some ARVs coming from originator companies must be bought in neighbouring countries with all the additional expenses and investment in human and administrative resources that this implies.

Registration of products is a major problem

- Companies have varying policies on product registration. Some companies offer discounted prices but do not register their products in specified countries. This practice makes the discounted price unattainable for everyone except those that have the possibility of asking for special authorisation from the Ministry of Health.
- National Drug Regulatory Authorities’ procedures for registering the products are sometimes slow, even if companies do everything necessary to get approval.
The investment needed to import drugs that are not registered is enormous. MSF has had to request special authorisation for Merck's efavirenz, GSK's abacavir, Abbott's lopinavir/ritonavir, Cipla's lamivudine/stavudine/nevirapine or Gilead's tenofovir in several countries, such as Cambodia, Uganda, Guatemala, Honduras, Laos or Ethiopia.

The channel chosen by the companies to distribute the products priced at lower price is too complex.

- For example, to benefit from the differential price from Abbott's products, the orders must be placed with Axios, an Irish NGO that works as intermediary. According to our staff, this is a burdensome procedure even for MSF procurement centers.
- Roche's products have to be ordered from Basel, and paid in Swiss francs, which is in practice difficult for procurement centres in developing countries.

3.2. At what price?

Even when the product is available on the market, prices quoted by manufacturers for this report may not represent the actual price for the following reasons:

- Excessive mark-ups by company local representatives in some countries;
- Lack of interest from companies to invest in exporting their products to small markets, for instance, generic companies in Latin America. In these cases, prices are often higher than those announced internationally by the companies;
- Lack of monitoring by responsible entities and donors of the prices paid by the different programmes for the same product;
- In countries outside sub-Saharan Africa and not classified as LDCs, prices can be as high as they are in Western countries, despite the fact that large numbers of people in these countries live below the poverty line. Generic companies have no geographical limits, but they do have quantity-related conditions in certain cases.

Despite the exemptions and the existence of specific second category prices for some products, prices paid in middle-income countries are still much higher than the offers published in this report (graph 1).

A good example of pricing problems is China, a non-LDC, non-African country, with an estimated one million people infected with HIV. There are very few generic products in the country, mainly due to intellectual property restrictions. Originator products are expensive and not always marketed in all dosages. For instance, stavudine from BMS is only marketed at the dosage of 20 mg. This makes it very difficult to treat children and doubles the pill burden for adults. Other important ARVs like lopinavir/ritonavir from Abbott are offered to MSF projects at US$ 5,000 per year – this is ten times more than the price for developing countries.

- Other middle-income countries, such as Ecuador or Georgia, pay unacceptably high prices for some products. For instance, Guatemala is paying US$ 2,500 per year for GSK's abacavir. The lack of competition for these new drugs lies behind high prices and lack of availability in the market.

For reasons described above, the current “differential pricing” practice cannot alone be considered the solution for increasing access to all needed ARVs worldwide. Access to life-saving medicines by the poorest populations should not depend on the goodwill of private companies. Making drugs affordable and available is a government responsibility. Where the political will exists, people pay less for their drugs and more people have access to them. International institutions and governments must work together to ensure that poor populations systematically benefit from lower prices which can be attained when sourcing from all available quality manufacturers.
Untangling the Web of Price Reductions

June 2005

www.accessmed-msf.org

Médecins Sans Frontières

Graph 1: The chart shows the differences in prices paid in different countries. Although prices paid by the poorest countries are indeed very close to the prices announced by companies, prices paid in middle-income countries are far too high compared with the offers. This is particularly true for most prices of the originator products applicable in middle-income countries.

Source: Global Fund Price reporting Mechanism. The GF pricing reporting site was consulted from June 6th to June 14th 2005, taking the minimum and the maximum reported prices from 2004 onwards. Minimum prices correspond with orders made by sub-Saharan African countries or LDCs outside Africa. Maximum prices correspond to non-African, non-LDC recipient countries.

Comparison between prices published in this report and prices reported by Global Fund

<table>
<thead>
<tr>
<th>Drug</th>
<th>Lowest price offered by companies</th>
<th>Highest price reported to GF</th>
<th>Lowest price reported to GF</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZT/3TC</td>
<td>GSK</td>
<td>Cipla</td>
<td>BMS</td>
</tr>
<tr>
<td>d4T 40</td>
<td>Merck</td>
<td>Cipla</td>
<td>Roche</td>
</tr>
<tr>
<td>EVF 200</td>
<td>Cipla</td>
<td>Cipla</td>
<td>Abbott</td>
</tr>
<tr>
<td>NFV</td>
<td>Abbott</td>
<td>Strides</td>
<td></td>
</tr>
<tr>
<td>ritonavir</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

USD/year
Prices of medicines recommended as 1st and 2nd line by WHO. June 2005

Graph 2: The chart shows the best prices for most drugs used in WHO recommended 1st (shaded bars) and 2nd line (solid bars) drugs. Prices indicated in the graph are the lowest amongst all surveyed manufacturers for this report. The figure over the columns shows the number of producers included in this report and having answered to Sources and Prices survey (Sources and prices of selected medicines and diagnostics for people living with HIV/AIDS, UNICEF-UNAIDS-WHO-MSF, June 2004). There are other reasons lying behind the high prices of some ARVs that are not included in this graph.
Sample of ARV triple-combination: stavudine (d4T) + lamivudine (3TC) + nevirapine (NVP). Lowest world prices per patient per year. Generic competition has shown to be the most effective means of lowering drug prices. During the last four years, originator companies have often responded to generic competition.

Determining the patent status of essential medicines in developing countries”, Health Economies and Drugs, EDM Series No. 17, UNAIDS/WHO/MSF, 2004 [3]

“Drug patents under the spotlight. Sharing practical knowledge about pharmaceutical patents” MSF, June 2004 [4]


[8] Other generic manufacturers known to be producing one or more ARVs but not included in this document are: Richmond Laboratorios, Panalab, Filaxis (Argentina); Pharmaquick (Benin); Far Manguinhos, FURP, Lapefe, Laob, Iquego, IVB (Brazil); Apotex, Novopharm (Canada); Shanghai Desano Biopharmaceutical company, Northeast General Pharmaceutical Factory (China); Biogen (Colombia); Stein (Costa Rica); Zydus Cadila Healthcare, SunPharma, EAS-SURG, Mac Leods, IPCA (India); LG Chemicals, Samchully, Korea United Pharm Inc. (Korea); Protein, Pisa (Mexico); Andromaco (Spain); Aspen (South Africa); T.O. Chemecal (Thailand); Laboratorio Dosa S.A. (US), Varichem (Zimbabwe). This list is not exhaustive.

[9] Incoterms are standard trade definitions most commonly used in international sales contracts, as published by the International Chamber of Commerce, http://www.iccwbo.org/index_incoterms.s.asp

[10] “GAO Reprot to Congressional Requesters. GLOBAL HIV/AIDS EPIDEMIC. Selection of Antiretroviral Medications Provided under U.S. Emergency Plan is Limited”, page 24, GAO, January 2005.”In some cases a manufacturer’s prices include costs that other manufacturers do not include – such as shipping and insurance charges. We note where these differences exist, and have determined that they do not undermine the essential comparability of the prices presented in our report”


Table 1: 1st and 2nd category of prices offered by manufacturers for the different countries (yearly and unit prices)

<table>
<thead>
<tr>
<th>Drug Combination</th>
<th>Unit</th>
<th>Cipla</th>
<th>GSK 1st categ</th>
<th>GSK 2nd categ</th>
<th>Hetero Drugs Ltd</th>
<th>Ranbaxy</th>
</tr>
</thead>
<tbody>
<tr>
<td>abacavir</td>
<td>300mg, tablet</td>
<td>584 (0.8)</td>
<td>887 (1.215)</td>
<td>n/a</td>
<td>773 (1.058)</td>
<td>664 (0.91)</td>
</tr>
<tr>
<td></td>
<td>20mg/ml, oral solution</td>
<td>292 (0.1)</td>
<td>382 (0.131)</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>didanosine</td>
<td>100mg, tablets</td>
<td>197 (0.135)</td>
<td>310 (0.212)</td>
<td>n/a</td>
<td>234 (0.16)</td>
<td>280 (0.192)</td>
</tr>
<tr>
<td></td>
<td>250mg, enteric-coated caps</td>
<td>198 (0.543)</td>
<td>n/a</td>
<td>106 (0.29)</td>
<td>146 (0.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>400mg, enteric-coated caps</td>
<td>279 (0.764)</td>
<td>n/a</td>
<td>142 (0.39)</td>
<td>219 (0.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2g powder for reconstitution with water and with antacids</td>
<td>39 (2.160)</td>
<td>133 (7.370)</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>efavirenz</td>
<td>50mg</td>
<td>cap</td>
<td>169 (0.116)</td>
<td>311 (0.113)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>200mg</td>
<td>cap</td>
<td>438 (0.4)</td>
<td>372 (0.34)</td>
<td>500 (0.457)</td>
<td>920 (0.840)</td>
</tr>
<tr>
<td></td>
<td>600mg</td>
<td>tab</td>
<td>472 (1.292)</td>
<td>347 (0.95)</td>
<td>347 (0.095)</td>
<td>766 (2.1)</td>
</tr>
<tr>
<td></td>
<td>30mg/ml suspension</td>
<td>227 (0.069)</td>
<td>309 (0.094)</td>
<td>496 (0.151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>emtricitabine</td>
<td>200mg</td>
<td>cap</td>
<td>n/a</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>indinavir</td>
<td>400mg</td>
<td>cap</td>
<td>432 (0.296)</td>
<td>321 (0.220)</td>
<td>400 (0.274)</td>
<td>686 (0.470)</td>
</tr>
<tr>
<td>lamivudine</td>
<td>150mg</td>
<td>tab</td>
<td>66 (0.09)</td>
<td>73 (0.1)</td>
<td>69 (0.095)</td>
<td>53 (0.073)</td>
</tr>
<tr>
<td></td>
<td>300mg</td>
<td>tab</td>
<td>85 (0.233)</td>
<td>n/a</td>
<td>171 (0.234)</td>
<td>69 (0.095)</td>
</tr>
<tr>
<td></td>
<td>10mg/ml oral solution and syrup and dry syrup</td>
<td>61 (0.021)</td>
<td>58 (0.02)</td>
<td>82 (0.028)</td>
<td>n/a</td>
<td>76 (0.026)</td>
</tr>
<tr>
<td>lamivudine + efavirenz + didanosine</td>
<td>150+600+250 (EC)</td>
<td>3 cap</td>
<td>766 (2.1)</td>
<td>839 (2.3)</td>
<td></td>
<td>73 (0.10)</td>
</tr>
<tr>
<td></td>
<td>150+600+400 (EC)</td>
<td>3 cap</td>
<td>766 (2.1)</td>
<td>839 (2.3)</td>
<td></td>
<td>73 (0.10)</td>
</tr>
</tbody>
</table>
### Untangling the Web of Price Reductions

<table>
<thead>
<tr>
<th>Description</th>
<th>Unit</th>
<th>Brand 1st categ</th>
<th>Brand 2nd categ</th>
<th>Other Brands</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>lamivudine/zidovudine/abacavir</td>
<td>tab</td>
<td>GSK 1st categ</td>
<td>GSK 2nd categ</td>
<td>Hetero Drugs Ltd</td>
<td>Ranbaxy</td>
</tr>
<tr>
<td>300 + 150 + 300mg</td>
<td>tab</td>
<td>1241 (1.7)</td>
<td>n/a</td>
<td>992 (1.358)</td>
<td>1095 (1.5)</td>
</tr>
<tr>
<td>lamivudine/stavudine</td>
<td>tab</td>
<td>Aurobindo</td>
<td>Cipla</td>
<td>Hetero Drugs Ltd</td>
<td>Ranbaxy</td>
</tr>
<tr>
<td>150 + 30mg</td>
<td>tab</td>
<td>72 (0.099)</td>
<td>79 (0.108)</td>
<td>74 (0.101)</td>
<td>124 (0.17)</td>
</tr>
<tr>
<td>150 + 40mg</td>
<td>tab</td>
<td>80 (0.109)</td>
<td>85 (0.117)</td>
<td>81 (0.111)</td>
<td>131 (0.18)</td>
</tr>
<tr>
<td>lamivudine/stavudine/nevirapine</td>
<td>tab</td>
<td>Aurobindo</td>
<td>Cipla</td>
<td>GPO</td>
<td>Hetero Drugs Ltd</td>
</tr>
<tr>
<td>150 + 30 + 200mg</td>
<td>tab</td>
<td>144 (0.198)</td>
<td>175 (0.24)</td>
<td>341 (0.467)</td>
<td>147 (0.201)</td>
</tr>
<tr>
<td>150 + 40 + 200mg</td>
<td>tab</td>
<td>152 (0.208)</td>
<td>182 (0.25)</td>
<td>375 (0.514)</td>
<td>161 (0.221)</td>
</tr>
<tr>
<td>lamivudine/zidovudine</td>
<td>tab</td>
<td>Aurobindo</td>
<td>Cipla</td>
<td>GSK 1st categ</td>
<td>GSK 2nd categ</td>
</tr>
<tr>
<td>150 + 300mg</td>
<td>tab</td>
<td>204 (0.28)</td>
<td>182 (0.25)</td>
<td>237 (0.325)</td>
<td>n/a</td>
</tr>
<tr>
<td>lamivudine/zidovudine/nevirapine</td>
<td>tab</td>
<td>Aurobindo</td>
<td>Cipla</td>
<td>Hetero Drugs Ltd</td>
<td>Ranbaxy</td>
</tr>
<tr>
<td>150 + 300 + 200mg</td>
<td>tab</td>
<td>257 (0.352)</td>
<td>255 (0.35)</td>
<td>281 (0.385)</td>
<td>292 (0.4)</td>
</tr>
<tr>
<td>lopinavir/ritonavir</td>
<td>cap</td>
<td>Abbott 1st categ</td>
<td>Abbott 2nd categ</td>
<td>Hetero Drugs Ltd</td>
<td></td>
</tr>
<tr>
<td>133.3 + 33.3mg</td>
<td>cap</td>
<td>500 (0.228)</td>
<td>n/a</td>
<td>1898 (0.867)</td>
<td></td>
</tr>
<tr>
<td>80 + 20mg/ml oral solution</td>
<td>ml</td>
<td>152 (0.139)</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>nelfinavir</td>
<td>g</td>
<td>Aurobindo</td>
<td>Cipla</td>
<td>GPO</td>
<td>Hetero Drugs Ltd</td>
</tr>
<tr>
<td>250mg (3)</td>
<td>tab</td>
<td>1533 (0.42)</td>
<td>1423 (0.39)</td>
<td>1599 (0.438)</td>
<td>1217 (0.333)</td>
</tr>
<tr>
<td>50mg/g oral powder</td>
<td>g</td>
<td>1962 (0.224)</td>
<td>2243 (0.256)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>nevirapine</td>
<td>ml</td>
<td>Aurobindo</td>
<td>Boehringer 1st categ</td>
<td>Boehringer 2nd categ</td>
<td>Cipla</td>
</tr>
<tr>
<td>200mg</td>
<td>tab</td>
<td>112 (0.153)</td>
<td>438 (0.6)</td>
<td>n/a</td>
<td>73 (0.1)</td>
</tr>
<tr>
<td>10mg/ml suspension</td>
<td>ml</td>
<td>411 (0.075)</td>
<td>400 (0.073)</td>
<td>n/a</td>
<td>137 (0.025)</td>
</tr>
<tr>
<td>ritonavir</td>
<td>ml</td>
<td>Abbott 1st categ</td>
<td>Abbott 2nd categ</td>
<td>Aurobindo</td>
<td>Cipla</td>
</tr>
<tr>
<td>100mg</td>
<td>cap</td>
<td>83 (0.114)</td>
<td>n/a</td>
<td>336 (0.46)</td>
<td>339 (0.464)</td>
</tr>
<tr>
<td>80mg/ml oral solution</td>
<td>ml</td>
<td>79 (0.93)</td>
<td>n/a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Unit</td>
<td>Manufacturer</td>
<td>Price 1st category</td>
<td>Price 2nd category</td>
<td>GPO</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------</td>
<td>---------------</td>
<td>--------------------</td>
<td>--------------------</td>
<td>-----</td>
</tr>
<tr>
<td>saquinavir</td>
<td>cap</td>
<td>Hetero Drugs Ltd</td>
<td>1022 (0.28)</td>
<td>989 (0.271)</td>
<td>1327 (0.606)</td>
</tr>
<tr>
<td>stavudine</td>
<td>cap</td>
<td>BMS</td>
<td>0.094</td>
<td>0.094</td>
<td>0.07</td>
</tr>
<tr>
<td>15mg</td>
<td>cap</td>
<td>Aurobindo</td>
<td>n/a</td>
<td>n/a</td>
<td>0.04</td>
</tr>
<tr>
<td>20mg</td>
<td>cap</td>
<td>BMS</td>
<td>0.094</td>
<td>0.094</td>
<td>0.07</td>
</tr>
<tr>
<td>30mg</td>
<td>cap</td>
<td>BMS</td>
<td>36 (0.05)</td>
<td>60 (0.082)</td>
<td>21 (0.029)</td>
</tr>
<tr>
<td>40mg</td>
<td>cap</td>
<td>BMS</td>
<td>39 (0.054)</td>
<td>77 (0.105)</td>
<td>25 (0.035)</td>
</tr>
<tr>
<td>1mg/ml powder for syrup</td>
<td>ml</td>
<td>Gilead</td>
<td>153 (0.021)</td>
<td>80 (0.011)</td>
<td>23 (0.016)</td>
</tr>
<tr>
<td>5mg/ml powder for syrup</td>
<td>ml</td>
<td>Gilead</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>tenofovir disoproxil fumarate</td>
<td>tab</td>
<td>Gilead</td>
<td>301 (0.824)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>tenofovir disoproxil</td>
<td>tab</td>
<td>Gilead</td>
<td>362 (0.991)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>fumarate/emtricitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>zidovudine</td>
<td>cap</td>
<td>Cipla</td>
<td>140 (0.192)</td>
<td>285 (0.39)</td>
<td>212 (0.29)</td>
</tr>
<tr>
<td>100mg</td>
<td>cap</td>
<td>Cipla</td>
<td>241 (0.33)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>250mg</td>
<td>cap</td>
<td>Cipla</td>
<td>117 (0.16)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>300mg</td>
<td>tab</td>
<td>Combino Pharm</td>
<td>131 (0.18)</td>
<td>285 (0.39)</td>
<td>212 (0.29)</td>
</tr>
<tr>
<td>10mg/ml syrup and 50mg/5ml oral solution</td>
<td>ml</td>
<td>GSK 1st category</td>
<td>130 (0.021)</td>
<td>223 (0.036)</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GSK 2nd category</td>
<td>n/a</td>
<td>n/a</td>
<td>130 (0.021)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GPO</td>
<td>277 (0.38)</td>
<td>134 (0.183)</td>
<td>161 (0.22)</td>
</tr>
</tbody>
</table>

n/a = discounted price not available.
Price of products pre-qualified by WHO (23rd edition of WHO Pre-Qualified List) appear in bold.
BMS sells ddI in other doses (per mg price remains the same).
The daily dose referred to is 800mg IDV twice daily with ritonavir 100mg twice daily as booster as recommended by WHO. The prescribing information given by the manufacturer is 800mg three times daily (price US$600/year).
The daily dose referred to is 1250 mg twice daily although the dosage of 9 tablets (3 tablets three times a day) can also be used.
Cipla PMTCT a 0.080 ml en envase de 25 ml.
The daily dose referred to is 100mg twice daily, for use as booster medication. This dose is not indicated in the manufacturer’s label.
Saquinavir should be used in combination with low-dose ritonavir as Saquinavir/Ritonavir 1000mg/100mg twice daily.
Not possible to use stavudine 15 mg capsule for 15 kg patient.
Not possible to use zidovudine 100 mg capsule for 15 kg patient.
GPO, has AZT at 0.021 in 60 ml bottle.
According to WHO treatment guidelines, the pediatric dosage of NVP is 120 to 200 mg/m2/dose, twice daily. For these calculations we considered 160mg/m2.
According to WHO treatment guidelines, the pediatric dosage of NV is 55 to 65 mg/m2/dose, twice daily. For these calculations we considered 60mg/m2.
Gilead 1st category price applies to some middle-income countries. See Table 2 for conditions.

Untangling the Web of Price Reductions • June 2005 • www.accessmed-msf.org • Médecins Sans Frontières
<table>
<thead>
<tr>
<th>Company</th>
<th>Eligibility (countries)</th>
<th>Eligibility (body)</th>
<th>Additional comments</th>
<th>Delivery of goods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>All African countries and LDCs outside of Africa</td>
<td>Governments, NGOs, UN system organizations and other national and international health institutions</td>
<td></td>
<td>FOB</td>
</tr>
<tr>
<td>Aurobindo</td>
<td>No restriction</td>
<td>NGOs and Governmental Organizations</td>
<td>Prices available for at least 1,000,000 units for each product per single shipment.</td>
<td>Payment by letter of credit. FOB Hyderabad (India)</td>
</tr>
<tr>
<td>BMS</td>
<td>Sub-Saharan Africa, Haiti, Mauritius, Cambodia, Vietnam (For other developing countries, prices negotiated on a case by case basis with BMS local market representative.)</td>
<td>Both private and public sector organizations that are able to provide effective, sustainable and medically sound care and treatment of HIV/AIDS are eligible.</td>
<td></td>
<td>DDU to French Speaking Africa and CIF incoterm for English Speaking Africa (Kenya, Uganda, Tanzania, Ethiopia, Nigeria, Ghana, Eritrea)</td>
</tr>
<tr>
<td>Boehringer-Ingelheim</td>
<td>All World Bank low-income countries and sub-Saharan Africa. (Other countries on a case-by-case basis.)</td>
<td>Governments, NGOs and other partners who can guarantee that the programme is run in a responsible manner.</td>
<td></td>
<td>CIF</td>
</tr>
<tr>
<td>Cipla</td>
<td>No restriction</td>
<td>No restriction</td>
<td>No quantity related conditions. Prices are as per table 1 however for larger quantities the prices are negotiable.</td>
<td>FOB Mumbai (India) or CIF – Freight charges separately on actual.</td>
</tr>
<tr>
<td>Combino Pharm</td>
<td>No restriction</td>
<td>No restriction</td>
<td>Delivery terms 120 days. No minimum order required unless any special labeling is required (standard labeling is in Spanish): order of a complete batch. Pack of 60 or 300 capsules available for ZDV.</td>
<td>FOB Barcelona (Spain)</td>
</tr>
<tr>
<td>Gilead</td>
<td>95 nations including all of Africa and 15 other UN-designated ‘least developed’ countries.</td>
<td>Organizations that provide HIV treatment in the 68 countries covered by the Gilead Global Access programme will be able to receive Viread at the access price. Applications will go through a review process.</td>
<td>Gilead works with several distributors in Africa to facilitate low cost local distribution channels.</td>
<td>FOB</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>Least Developed Countries (LDCs) plus sub-Saharan Africa. All projects fully financed by the Global Fund to fight AIDS, TB and Malaria as well as projects funded by PEPFAR.</td>
<td>Governments, aid organizations, charities, UN agencies, other not-for-profit organizations and international procurement agencies.</td>
<td>In sub-Saharan Africa employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics or similar arrangements are also eligible. In sub-Saharan Africa employers there who offer HIV/AIDS care and treatment directly to their staff</td>
<td>CIP</td>
</tr>
<tr>
<td>Company</td>
<td>Eligibility (countries)</td>
<td>Eligibility (body)</td>
<td>Additional comments</td>
<td>Delivery of goods</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>GPO</td>
<td>(For middle income developing countries public sector prices negotiated on a case-by-case basis bilaterally through the AAI).</td>
<td>Not-for-profit organizations and governments</td>
<td>Payment by signed letter of credit.</td>
<td>FOB Bangkok (Thailand)</td>
</tr>
<tr>
<td>Hetero Drugs Ltd</td>
<td>No restriction</td>
<td>Private sector, public sector and NGOs</td>
<td>Prices could be negotiated on individual basis according commercial terms.</td>
<td>FOB Mumbai (India)</td>
</tr>
<tr>
<td>Merck &amp; Co. Inc</td>
<td>First category of countries: Low Human Development Index (HDI) countries plus medium HDI countries with adult HIV prevalence of 1% or greater*.*</td>
<td>Governments, international organizations, NGOs, private sector organizations (e.g. employers, hospitals and insurers).</td>
<td>Merck &amp; Co. Inc does not rule out supplying ARVs to patients through retail pharmacies. Although Romania does not fall under these categories it also benefits from these prices due to a government commitment to a programme of universal access.</td>
<td>CIP</td>
</tr>
<tr>
<td>Ranbaxy</td>
<td>No restriction</td>
<td>NGOs and Governments or Programs supported by them</td>
<td>Confirmed letter of credit or advance payment preferred for new customers</td>
<td>FOB Delhi/Mumbai (India)</td>
</tr>
</tbody>
</table>
| Roche               | First category of countries: All countries in sub-Saharan Africa and all UN defined Least Developed Countries  
Second category of countries: Low income countries and lower middle income countries – as classified by the World Bank. | Governments, Non Profit Institutional Providers of HIV care, NGOs. | CAD (Cash Against Documents) 30 days at sight. Minimum order and delivery amount per shipment is CHF 10,000 (US$ 8,179)                                                                                                                                                  | FCA Basel (CH), |
| Strides Arcolab Ltd | No restriction                                                                         | Governments, non profit institutional providers of HIV treatment, NGOs | Payment by signed letter of credit                                                                                                                                                                                                                                 | FOB Bangalore (India) |
Annex 1: Least Developed Countries (LDCs)

Source: UNCTAD
http://www.unctad.org/Templates/WebFlyer.asp?intItemID=2161&lang=1
Fifty countries are currently designated least developed countries (LDCs). The list is reviewed every three years.

Afghanistan; Angola; Bangladesh; Benin; Bhutan; Burkina Faso; Burundi; Cambodia; Cape Verde; Central African Republic; Chad; Comoros; Democratic Republic of Congo; Djibouti; Equatorial Guinea; Eritrea; Ethiopia; Gambia; Guinea; Guinea-Bissau; Haiti; Kenya; Lesotho; Madagascar; Malawi; Mali; Mauritania; Mozambique; Niger; Nigeria; Pakistan; Rwanda; Senegal; Sierra Leone; Tanzania (U. Rep. of); Timor-Leste; Togo; Uganda; Yemen; Zambia; Zimbabwe.

Annex 2: Human Development Index (HDI)


Low human development
Angola; Benin; Burkina Faso; Burundi; Central African Republic; Chad; Congo; Congo (Dem. Rep. of the); Côte d’Ivoire; Djibouti; Eritrea; Ethiopia; Gambia; Guinea; Guinea-Bissau; Haiti; Kenya; Lesotho; Madagascar; Malawi; Mali; Mauritania; Mozambique; Niger; Nigeria; Pakistan; Rwanda; Senegal; Sierra Leone; Tanzania (U. Rep. of); Timor-Leste; Togo; Uganda; Yemen; Zambia.

Medium human development
Albania; Algeria; Armenia; Azerbaijan; Bangladesh; Belarus; Belize; Bhutan; Bolivia; Bosnia and Herzegovina; Botswana; Brazil; Bulgaria; Cambodia; Cameroon; Cape Verde; China; Colombia; Comoros; Dominica; Dominican Republic; Ecuador; Egypt; El Salvador; Equatorial Guinea; Fiji; Gabon; Georgia; Ghana; Grenada; Guatemala; Guyana; Honduras; India; Indonesia; Iran (Islamic Rep. of); Jamaica; Jordan; Kazakhstan; Kyrgyzstan; Lao People’s Dem.Rep.; Lebanon; Libyan Arab Jamahiriya; Macedonia (TFYR); Malaysia; Maldives; Mauritius; Moldova (Rep. of); Mongolia; Morocco; Myanmar; Namibia; Nepal; Nicaragua; Occupied Palestinian Territories; Oman; Panama; Papua New Guinea; Paraguay; Peru; Philippines; Romania; Russian Federation; Saint Lucia; Saint Vincent and the Grenadines; Samoa (Western); São Tomé & Príncipe; Saudi Arabia; Solomon Islands; South Africa; Sri Lanka; Sudan; Suriname; Swaziland; Syrian Arab Republic; Tajikistan; Thailand; Tonga; Tunisia; Turkey; Turkmenistan; Ukraine; Uzbekistan; Vanuatu; Venezuela; Viet Nam.

Annex 3: Sub-Saharan countries

Source: World Bank (May 2005)
http://www.worldbank.org/data/countryclass/classgroups.htm#Sub_Saharan_Africa
Angola; Benin; Botswana; Burkina Faso; Burundi; Cameroon; Cape Verde; Central African Republic; Chad; Comoros; Congo (Dem. Rep.); Congo (Rep.); Côte d’Ivoire; Equatorial Guinea; Eritrea; Ethiopia; Gabon; Gambia; Ghana; Guinea; Guinea-Bissau; Kenya; Lesotho; Liberia; Madagascar; Malawi; Mali;
Mauritania; Mauritius; Mayotte; Mozambique; Namibia; Niger; Nigeria; Rwanda; São Tomé and Principe; Senegal; Seychelles; Sierra Leone; Somalia; South Africa; Sudan; Swaziland; Tanzania; Togo; Uganda; Zambia; Zimbabwe.

**Annex 4: World Bank low-income economies**


**Low-income economies**

Afghanistan; Angola; Bangladesh; Benin; Bhutan; Burkina Faso; Burundi; Cambodia; Cameroon; Central African Republic; Chad; Comoros; Congo (Dem. Rep.); Congo (Rep.); Côte d’Ivoire; Equatorial Guinea; Eritrea; Ethiopia; Gambia, The; Ghana; Guinea; Guinea-Bissau; Haiti; India; Kenya; Korea, Dem. Rep.; Kyrgyz Republic; Lao PDR; Lesotho; Liberia; Madagascar; Malawi; Mali; Mauritania; Moldova; Mongolia; Mozambique; Myanmar; Nepal; Nicaragua; Niger; Nigeria; Pakistan; Papua New Guinea; Rwanda; São Tomé and Principe; Senegal; Sierra Leone; Solomon Islands; Somalia; Sudan; Tajikistan; Tanzania; Timor-Leste; Togo; Uganda; Uzbekistan; Vietnam; Yemen (Rep.); Zambia; Zimbabwe.

**Lower-middle-income economies**

Albania; Algeria; Armenia; Azerbaijan; Belarus; Bolivia; Bosnia and Herzegovina; Brazil; Bulgaria; Cape Verde; China; Colombia; Cuba; Djibouti; Dominican Republic; Ecuador; Egypt; Arab Rep.; El Salvador; Fiji; Georgia; Guatemala; Guyana; Honduras; Indonesia; Iran, Islamic Rep.; Iraq; Jamaica; Jordan; Kazakhstan; Kiribati; Macedonia; FYR; Maldives; Marshall Islands; Micronesia, Fed. Sts.; Morocco; Namibia; Paraguay; Peru; Philippines; Romania; Russian Federation; Samoa; Serbia and Montenegro; South Africa; Sri Lanka; Suriname; Swaziland; Syrian Arab Republic; Thailand; Tonga; Tunisia; Turkey; Turkmenistan; Ukraine; Vanuatu; West Bank and Gaza.

**Upper-middle-income economies**

American Samoa; Antigua and Barbuda; Argentina; Barbados; Belize; Botswana; Chile; Costa Rica; Croatia; Czech Republic; Dominica; Estonia; Gabon; Grenada; Hungary; Latvia; Lebanon; Libya; Lithuania; Malaysia; Mauritius; Mayotte; Mexico; Northern Mariana Islands; Oman; Palau; Panama; Poland; Saudi Arabia; Seychelles; Slovak Republic; St. Kitts and Nevis; St. Lucia; St. Vincent and the Grenadines; Trinidad and Tobago; Uruguay; Venezuela, RB.

**Annex 5: Company contacts**

**Abbott:**

Rob Dintruff  
Email: rob.dintruff@abbott.com

**AXIOS International manages the request process:**

The Programme Manager  
Access to HIV Care Programme  
AXIOS International  
P.O. Box 6924  
Kampala, Uganda.  
Tel: +256 75 693 756  
Fax:+256 41 543 021  
Email: AccesstoHIVCare@axiosint.com  
Website: [www.accesstohivcare.org](http://www.accesstohivcare.org)

**Aurobindo Pharma Ltd:**

Mr. A.Vijaykumar  
Head – Anti Retrovirals Project  
Tel: +91 40 2304 4070  
Or +91 98481 10877 (Mobile)  
Fax: +91 40 23044058  
Email: vk_akula@aurobindo.com

**Boehringer Ingelheim:**

Helmut Leuchten  
CD Marketing Prescription Medicines  
Head of Corporate Department  
HIV Virology  
Phone: + 49 6132 77-8486  
Fax: +49 6132 77-3829  
Email: helmut.leuchten@ing.boehringer-ingelheim.com

**Bristol-Myers Squibb Co:**

All countries with the exception of Southern Africa: information can be obtained from Mrs Marie-Astrid Mercier, BMS Access Coordinator in BMS Paris office (marie-astrid.mercier@bms.com)

Southern Africa: information can be obtained from Mrs Tamany Geldenhuys in BMS offices in Johannesburg (tamany.geldenhuys@bms.com).

Michael Rabbow (for the Viramune MTCT donation program)  
Marketing Prescription Medicines  
CG HIV-Specialists/Virologists  
Tel: + 49 6132 77·92701  
Fax: + 49 6132 77-38 29  
Email: rabbow@ing.boehringer-ingelheim.com
Cipla Ltd:
Mr. Sanjeev Gupte, General Manager-Exports
Mr. Shailesh Pednekar
Executive-Exports, Cipla Limited
Tel: +91 22 23021397 (Direct)
23095521 23092891
Fax: +91 22
23070013/23070393/23070385
Email: exports@cipla.com and ciplaexp@cipla.com

Combinopharm:
Ms. Silvia Gil
Managing Director
Combinopharm
Tel: + 34 93 48 08 833
Fax: + 34 93 48 08 832
Email: sgil@combino-pharm.es

Gilead
Programme Access
Deborah Ovadia
Gilead Global Access Program Manager
Gilead Sciences, Inc
333 Lakeside Drive
Foster City, California 94404 USA
Tel: 1-800-G I L E A D-5, Option 1
Fax: +1-650-522-5870
Email: ARVaccess@gilead.com
www.gileadaccess.org

GlaxoSmithKline:
Isabelle Girault
Director, Government Affairs
HIV & AIDS
Tel: + 44 (o) 20 8047 5488
Fax: + 44 (o) 20 8047 6957
Email: isabelle.s.girault@gsk.com

GPO:
Mr. Sukhum Virattipong
International Business Director
Tel: +662 3545587, 2038850
Fax: +662 3548858, 3548777

Hetero Drugs Limited:
Hetero House, H.No.:8-3-166/7/1, Erragadda, Hyderabad-500 018 India.
Tel: 0091-40-23704923 / 24
Tel (Direct):0091-40-23818029
Email: msreddy@heterodrugs.com

Merck & Co. Inc.:
Samir A. Khalil
Executive Director HIV Policy & External Affairs
Human Health Europe, Middle East & Africa
Merck & Co., Inc/WS2A-55
One Merck Drive, Whitehouse Station NJ 08889-0100 USA
Tel: +1 908 423 6440
Fax: +1 908 735 1839
Email: samir_khalil@merck.com

Ranbaxy:
Mr. Sandeep Juneja
Ranbaxy Laboratories Limited
Tel: + 91 124 518 59 06 (Direct)
or + 91 124 513 50 00
Fax: + 91 124 516 60 35
Email: sandeep.juneja@ranbaxy.com
www.aidonaids.com
www.ranbaxy.com

Roche:
For information regarding quotations and deliveries to customers contact:
Hanspeter Wälchli
Logistics Sales International
Customers Dept. PTGS-I
4303 Kaiseraugst / Switzerland
Tel: +41 61 688 1060
Fax: +41 61 687 1815
Email: hanspeter.waelchli@roche.com

Strides Arcolab Ltd:
Mrs. Aloka Sengupta
Asst. Vice President ATM
Strides House, Bilekahalli
Bannergatta Road
Bangalore 560 076, INDIA
Tel: +91-80-57580748
Mobile : +91 98450 24470
Fax: 91-80-26583538
Email: aloka.sengupta@stridesarco.com

Asst. Vice President ATM
Strides House, Bilekahalli
Bannergatta Road
Bangalore 560 076, INDIA
Tel: 91-80-26581343/44/46,
+91-80-26584529(Direct)
Fax: 91-80-26583538/26584330
Email: aloka@stridesarco.com

Médecins Sans Frontières • www.accessmed-msf.org • June 2005 • Untangling the Web of Price Reductions • 19
**Glossary**

**3TC** lamivudine; nucleoside analogue reverse transcriptase inhibitor

**ABC** abacavir; nucleoside analogue reverse transcriptase inhibitor

**AIDS** Acquired Immune Deficiency Syndrome

**ARVs** Antiretroviral drugs

**BMS** Bristol-Myers Squibb

**CDC** Centres for Disease Control and Prevention

**CIF** ‘Cost Insurance and Freight’ means that the seller delivers when the goods pass the ship’s rail in the port of shipment. The seller must pay the costs and freight necessary to bring the goods to the named port of destination BUT the risk of loss or damage to the goods, as well as any additional costs due to events occurring after the time of delivery, are transferred from the seller to the buyer.

**CIP** ‘Carriage and Insurance paid to...’ means that the seller delivers the goods to the carrier nominated by him but the seller must in addition pay the cost of carriage necessary to bring the goods to the named destination. This means that the buyer bears all the risks and any additional costs occurring after the goods have been so delivered. However, in CIP the seller also has to procure insurance against the buyer’s risk of loss of or damage to the goods during the carriage. Consequently, the seller contracts for insurance and pays the insurance premium.

**d4T** stavudine; nucleoside analogue reverse transcriptase inhibitor

**ddI** didanosine; nucleoside analogue reverse transcriptase inhibitor

**DDU** ‘Delivered duty unpaid’ means that the seller delivers the goods to the buyer, not cleared for import, and not unloaded from any arriving means of transport at the named place of destination. The seller has to bear the costs and risks involved in bringing the goods thereto, other than, where applicable, any ‘duty’ (which term includes the responsibility for the risks of the carrying out of the customs formalities, and the payment of formalities, customs duties, taxes and other charges) for import in the country of destination. Such ‘duty’ has to be borne by the buyer as well as any costs and risks caused by his failure to clear the goods for the import time.

**EML** Essential Medicines List. First published by WHO in 1977, it is meant to identify a list of medicines, which provide safe and effective treatment for the infectious and chronic diseases, which affect the vast majority of the world’s population. The 12th Updated List was published in April 2002 and includes 12 antiretrovirals.

**EFV or EFZ** efavirenz; non-nucleoside analogue reverse transcriptase inhibitor

**EXW** ‘Ex-works’ means that the seller delivers when he places the goods at the disposal of the buyer at the seller’s premises or another named place (i.e. works, factory, warehouse etc.) not cleared for export and not loaded on any collecting vehicle.

**FOB** ‘Free on board’ means that the seller delivers when the goods pass the ship’s rail at the named port of shipment. This means that the buyer has to bear all costs and risks of loss or damage to the goods from that point. The FOB term requires the seller to clear the goods for export.

---

**Untangling the Web of Price Reductions**

June 2005 • www.accessmed-msf.org • Médecins Sans Frontières
Generic drug According to WHO, a pharmaceutical product usually intended to be interchangeable with the originator product, which is usually manufactured without a license from the originator company.

GPO The Government Pharmaceutical Organization (Thailand)

GSK GlaxoSmithKline

HIV Human Immunodeficiency Virus

IDV indinavir; protease inhibitor

LDCs Least Developed Countries, according to United Nations classification

MSD Merck Sharp & Dome (Merck & Co., Inc.)

MSF Mèdecins Sans Frontières

NGO Non Governmental Organization

NFV nelfinavir; protease inhibitor

NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor

NRTI Nucleoside Analogue Reverse Transcriptase Inhibitor

NRTI Nucleotide Reverse Transcriptase Inhibitor

NVP nevirapine; non-nucleoside analogue reverse transcriptase inhibitor

PMTCT Prevention of Mother-To-Child Transmission

r low dose ritonavir used as a booster; protease inhibitor

SQV hgc saquinavir hard gel capsules; protease inhibitor

SQV sgc saquinavir soft gel capsules; protease inhibitor

TDF tenofovir; nucleotide reverse transcriptase inhibitor


UNDP United Nations Development Programme

WHO World Health Organization

ZDV zidovudine; nucleoside analogue reverse transcriptase inhibitor
Untangling the web of price reductions:
a pricing guide for the purchase of ARVs for developing countries

8th Edition

Campaign for Access to Essential Medicines
Médecins Sans Frontières
Rue de Lausanne 78, CP 116
CH-1211 Geneva 21, Switzerland

Tel: + 41 (0) 22 849 84 05
Fax: + 41 (0) 22 849 84 04

email: access@geneva.msf.org
http://www.accessmed-msf.org

Design and artwork: Twenty 3 Crows Ltd +44 (0) 1848 200401